On the other hand, the progression of prostate cancer frequently involves changes in the AR signaling pathway, including AR mutations, gene rearrangements, and the reactivation of signaling pathways, which frequently leads to increased resistance of prostate cancer cells to androgen deprivation therapy (9, 10). This evidence concerns the gene AR and Familial prostate cancer.